'1805
Rheumatoid Arthritis
Key Facts
About Revolo Biotherapeutics
Revolo Biotherapeutics is a private, venture-funded biotechnology company pioneering an upstream, disease-agnostic approach to treating immune-mediated conditions. Its core technology involves peptide-based therapies that simultaneously upregulate regulatory T/B cells and downregulate effector T cells, aiming for rapid, prolonged effect without systemic immune suppression. The lead candidate '1104 has completed a Phase 2 trial in eosinophilic esophagitis (EoE), with plans for a larger Phase 2 trial in 2025, while '1805 is being prepared for Phase 2 trials in rheumatoid arthritis and ulcerative colitis. The company's strategy includes exploring convenient subcutaneous and sublingual administration routes to potentially disrupt the current treatment landscape.
View full company profileAbout Revolo Biotherapeutics
Revolo Biotherapeutics is a private, venture-funded biotechnology company pioneering an upstream, disease-agnostic approach to treating immune-mediated conditions. Its core technology involves peptide-based therapies that simultaneously upregulate regulatory T/B cells and downregulate effector T cells, aiming for rapid, prolonged effect without systemic immune suppression. The lead candidate '1104 has completed a Phase 2 trial in eosinophilic esophagitis (EoE), with plans for a larger Phase 2 trial in 2025, while '1805 is being prepared for Phase 2 trials in rheumatoid arthritis and ulcerative colitis. The company's strategy includes exploring convenient subcutaneous and sublingual administration routes to potentially disrupt the current treatment landscape.
View full company profileTherapeutic Areas
Other Rheumatoid Arthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Early Detection Test for Rheumatoid Arthritis | Age Labs | Development |
| Piclidenoson (CF101) | Can Fite Biopharma | Phase II/III |
| ERNA-201 | Eterna Therapeutics | Preclinical |
| Tc99m Tilmanocept | Navidea Biopharmaceuticals | Phase 2/3 |
| Monoclonal Antibody Biosimilar (Anti‑TNF) | USV Biologics Division | Phase 1 |
| Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure) | LFB | Pre-clinical |
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| LFD-200 | Lifordi Immunotherapeutics | Phase 1 |
| MEV-N01 | Mesenbio | Pre-clinical |
| CIT-013 | Citryll | Phase 2a |
| Restem-L | Restem | Phase 2 |
| ASIT Platform | Ahead Therapeutics | Pre-clinical |